Clinical Trial Update: OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism [NA]

View source ↗

Summary

A completed study examining the effects of osteoprotegerin (OPG) and soluble RANKL on bone mineral density in individuals with primary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Osteoprotegerin (OPG) (osteoprotegerin)
• Soluble RANKL (sRANKL) (soluble receptor activator of nuclear factor kappa-B ligand)

Snippet

Sponsor: Wroclaw Medical University | Conditions: Primary Hyperparathyroidism | NA | Status: COMPLETED